Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.23.3
Subsequent Events (Details) - USD ($)
9 Months Ended
Oct. 31, 2023
Oct. 12, 2023
Sep. 30, 2023
Sep. 30, 2022
Oct. 18, 2023
Subsequent Events          
Cash payments for acquisition     $ 10,405,000 $ 0  
Subsequent Event | Tolerance Therapeutics          
Subsequent Events          
Interest in sales revenue (as a percent) 1.00%        
Cash payments for acquisition $ 20,000,000        
Subsequent Event | Soticlestat | Ovid          
Subsequent Events          
Interest in sales revenue (as a percent)         13.00%
Consideration paid for an interest in potential development milestone         $ 30,000,000
Subsequent Event | Revolving Credit Facility          
Subsequent Events          
Maximum borrowing capacity   $ 75,000,000      
Subsequent Event | Revolving Credit Facility | Minimum          
Subsequent Events          
Line of credit facility, interest rate (as a percent)   0.30%      
Subsequent Event | Revolving Credit Facility | Minimum | Base Rate          
Subsequent Events          
Variable rate   0.75%      
Subsequent Event | Revolving Credit Facility | Minimum | Secured Overnight Financing Rate (SOFR)          
Subsequent Events          
Variable rate   1.75%      
Subsequent Event | Revolving Credit Facility | Maximum          
Subsequent Events          
Line of credit facility, interest rate (as a percent)   0.45%      
Subsequent Event | Revolving Credit Facility | Maximum | Base Rate          
Subsequent Events          
Variable rate   1.50%      
Subsequent Event | Revolving Credit Facility | Maximum | Secured Overnight Financing Rate (SOFR)          
Subsequent Events          
Variable rate   2.50%